Curaleaf Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CURLF research report →
Range $6 – $6
Price Chart
About the company
Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities.
- CEO
- Boris Alexis Jordan
- IPO
- 2018
- Employees
- 5,554
- HQ
- Stamford, CT, US
Get TickerSpark's AI analysis on CURLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.62B
- P/E
- -211.91
- Fwd P/E
- 86.63
- PEG
- -0.56
- P/S
- 1.32
- P/B
- 2.39
- EV/EBITDA
- 14.64
- Div Yield
- 0.00%
- Gross Margin
- 43.73%
- Op Margin
- 0.80%
- Net Margin
- -0.90%
- ROE
- -1.47%
- ROIC
- 0.02%
Latest fiscal year · YoY change
- Revenue
- $1.29B+0.9%
- Gross Profit
- $498.20M+12.0%
- Op Income
- $25.90M
- Net Income
- $-235,115,003-3.7%
- EPS
- $-0.93-6.9%
- OCF Growth
- -9.3%
- FCF Growth
- +14.7%
- 52W High
- $15.15
- 52W Low
- $5.58
- 50D MA
- $9.22
- 200D MA
- $9.03
- Beta
- 1.61
- RSI (14)
- 31
- Avg Volume
- 214.06K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Curaleaf posted 11% revenue growth and solid EBITDA in Q3, while leaning into cost discipline, international expansion, and a cautious near-term outlook due to Germany pricing pressure.· November 3, 2026
- Q3 revenue rose 11% year over year to $353 million, with adjusted gross margin at 49% and adjusted EBITDA of $78 million (22% margin).
- Domestic revenue grew 8% and international revenue grew 28%; management said domestic growth ran for a third straight quarter and international remained strong despite Germany headwinds.
- The company said it is making progress on its cost savings plan, with core SG&A at 31% of revenue and a stated goal to cut expenses by $20 million in the second half of the year.
- Florida, the U.K., Germany, and Poland were key growth drivers, while Germany was hit by sharp price compression from competitor behavior.
- Fourth-quarter revenue is guided to grow 1% to 2% sequentially, implying about $358 million at the midpoint, but management expects gross margin and EBITDA to be pressured by temporary international issues.
Third quarter revenue was $353 million, up 11% year over year and 4% sequentially. Gross profit was $170 million; adjusted gross profit was $172 million; adjusted gross margin was 49%, down 190 basis points from last year. Adjusted EBITDA was $78 million, up 8% year over year, for a 22% margin. Net loss from continuing operations was $37 million, or $0.14 per share, versus a net loss of $54 million, or $0.24 per share, a year ago. Cash and cash equivalents were $105 million. Q3 operating cash flow from continuing operations was $22 million and free cash flow was $5 million. For Q4, revenue is expected to increase 1% to 2% sequentially, or about $358 million at the midpoint. Management said gross margin should be about 48% to 49% and EBITDA roughly flat with Q3, with full-year operating cash flow targeted at about $150 million and 2026 capex expected to be approximately $80 million.
Boris Jordan framed the quarter as evidence that Curaleaf’s “Build for Growth” strategy is working, emphasizing better yields, improved product quality, brand strength, and disciplined cost control. He sounded constructive on domestic demand, still confident on long-term international expansion, and upbeat about regulatory catalysts such as federal rescheduling and hemp-related market shifts. At the same time, he was notably cautious on Germany, saying price compression there has been severe and that Curaleaf will be selective until the market stabilizes.
Ed Kremer focused on the financial bridge from revenue growth to margins and cash flow. He highlighted 49% adjusted gross margin, 31% core SG&A as a percent of revenue, $117 million in SG&A, and $78 million in adjusted EBITDA, while noting that higher facilities costs, wholesale pressure, and Germany drove margin dilution. He also cited $105 million in cash, $17 million in capex, $22 million in operating cash flow, and said fourth-quarter operating cash flow should step up toward the full-year target of about $150 million as timing items normalize.
Analysts pressed management on the Aurora bid, Germany pricing, hemp, Florida expansion, and federal medical registrations. On Aurora, Boris Jordan said Curaleaf’s bid was just under 10% below Organigram’s on a closing-price basis, but that Curaleaf would need due diligence before improving its offer; he also argued the deal is about more than cultivation, including products and registrations. On Germany, he said prices had fallen from about $3 a gram to $0.90 a gram in one quarter and that Curaleaf is working with regulators on greenwashing enforcement. He also said Curaleaf has already received more than 80 DEA medical registrations, but export policy is not yet being addressed, and Florida remains attractive despite saturation because vertical integration and supply depth remain barriers to new entrants.
The bull case from the call is that Curaleaf is still growing at a healthy pace while improving efficiency: revenue rose 11%, domestic and international both grew, and SG&A leverage improved. Management also pointed to stronger yields, better brand performance, expanding store count in Florida, and upcoming catalysts from hemp restrictions, international product launches, and possible federal regulatory changes.
The main risks discussed were Germany’s severe price compression, macro pressure on the consumer, and seasonally promotional conditions that could keep margins under pressure into Q4. Management also flagged that the Aurora transaction may not proceed without due diligence, and that international pricing volatility could temporarily offset otherwise strong demand and growth.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.6%
- Shares Outstanding
- 233.65M
- Float Shares
- 169.66M
of shares held by institutions
2 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Nano Cap New Millennium Growth Fund L P | 25.20K | ▲ 10.20K |
| Ancora Advisors LLC | 33 | ▲ 33 |
Held by 4 ETFs
Biggest fund positions in CURLF by dollar value.
Our CURLF coverage
Recent articles, reports, and earnings notes.
No research on CURLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CURLF report →Curaleaf Opens First Sebring Dispensary, Expanding Florida Retail Footprint
prnewswire.com · Nov 17
Curaleaf Unlikely To Acquire Aurora Cannabis, But Long-Term Potential Remains
seekingalpha.com · Nov 13
Curaleaf Receives All Required Competition Law Clearances for Proposed Acquisition of Aurora Cannabis
prnewswire.com · Nov 10
The Big Winner From the Aurora Cannabis-Organigram Deal: Curaleaf
fool.com · Nov 9
Aurora Cannabis Stock: What Organigram's Buyout Means for Investors
zacks.com · Nov 4
Curaleaf Holdings, Inc. (CURLF) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 3
Curaleaf Holdings, Inc. (CURA:CA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Curaleaf Issues Statement Regarding Alternative Proposal for Aurora Cannabis
prnewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.